Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sifalimumab

Next Previous
Drug Profile

Sifalimumab

Alternative Names: Anti-IFNa MAb; MDX-1103; MEDI-545

Latest Information Update: 05 Nov 2023

Price :
€55 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex
  • Developer MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Interferon alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myositis; Psoriasis; Systemic lupus erythematosus

Most Recent Events

  • 19 Jul 2016 MedImmune completes its phase II trial for Systemic lupus erythematosus in Japan (NCT01031836)
  • 31 Mar 2015 Discontinued - Phase-II for Systemic lupus erythematosus in USA and Japan (SC)
  • 31 Mar 2015 Discontinued - Phase-II for Systemic lupus erythematosus in USA, Argentina, Brazil, Bulgaria, Canada, Chile, Colombia, France, Germany, Hungary, India, Italy, Jamaica, Japan, Mexico, Netherlands, Peru, Philippines, Poland, Romania, South Africa, Spain, Thailand and United Kingdom (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top